Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Sesame Care

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Sesame Care head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 4 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 6 · Grade B+

Sesame Care

Visit Sesame Care Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 87 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Sesame Care a bad call — it's best for shoppers who want genuine fda-approved brand-name glp-1s and the ability to pick their own provider and see the price up front, rather than one fixed compounded program. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
84
Supply Reliability
88
92
Transparency
84
94
Access Breadth
82
84
Clinical Oversight
88
80
Track Record
90
92
Invigor MedicalBrief Score 88 · 87Sesame Care

Price, coverage & the tracker

Invigor MedicalSesame Care
Brief Score88/100 (B+)87/100 (B+)
Semaglutide$199/moFrom $149/mo (brand Wegovy pill)
Tirzepatide$339/moBrand Zepbound (price varies)
CoverageNot disclosedNationwide marketplace
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.